They analyzed each closing stock price before and after the date of a public announcement and found that the average stock price 120 days before a phase III clinical trial announcement showed an increase of 13.7 percent for companies that reported positive trials and a 0.7 percent drop for those reporting negative trial results ( here is the abstract).